King of Prussia, PA
1 Years Ago
Center for Breakthrough Medicines is on track to be the largest single-site cell and gene therapy contract development and manufacturing organization in the world. Our comprehensive service offering accelerates speed to market through supply chain disruption mitigation strategies, end-to-end program management expertise and unique platform technology with the ability to follow a molecule from idea to commercialization. CBM’s integrated approach provides high quality and consistent end-to-end manufacturing capability including: Process and Analytical Development; Plasmid DNA production; Viral Vector Production of Lentivirus; AAV and Adenovirus; Testing and Analytics; Autologous, Allogeneic and Gene-edited Cell Therapy Bioprocessing; and Cell banking. CBM’s horizontal and vertical integration provides one source throughout a product’s life cycle.
CBM’s mission is to accelerate the delivery and affordability of lifesaving and life-changing therapies from discovery to market by offering a complete solution for the development and commercialization of cell and gene therapies.
CBM is located just outside of Philadelphia in the Heart of Cellicon Valley on The Discovery Labs campus set on 300 acres with 2.4 million square feet of life sciences lab and manufacturing space, allowing clients to scale their development and manufacturing needs without ever having to change sites, while providing employees a true community campus experience focused exclusively on life sciences.
The Director of Analytical Development for Flow Cytometry/Cell Biology will be responsible for providing senior leadership over the Flow Cytometry/Cell biology testing services supporting Cell and Gene Therapy Programs at Center for Breakthrough Medicines. The Director will be a key member of the Testing Leadership team and will be responsible for leading the development new Flow Cytometry/Cell biology methods, transitioning, and validating GMP test methods from Analytical Development and other cross-functional groups, and CBM’s clients. The Director will be responsible for managing a team of Cell and Gene Therapy scientists that will be directly responsible for development and method transfers and delivering results to our customers for complex characterization and product release methods. The Director will also be responsible for driving the strategy and execution of new analytical technologies and techniques to serve our clients, bringing cell and gene therapies from bench to bedside.
TBD